SCHEMBL6283832

SCHEMBL6283832

CC(=NNC(=N)N)c1cn(S(=O)(=O)c2ccc(Br)cc2)c2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.60
AKR1C1 Q04828 1/20 0.60
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PLK1 P53350 1/20 0.47
HDAC1 Q13547 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
HDAC2 Q92769 1/20 0.44
HTR6 P50406 5/20 0.44
ALOX5 P09917 4/20 0.42
PTGS2 P35354 1/20 0.42
TNF P01375 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 1/20 0.39
UBE2N P61088 1/20 0.39
TNFSF11 O14788 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6283829 1.00 AKR1C3 (0.60) AKR1C3AKR1C1LMNASMN1; SMN2MEN1
SCHEMBL6286909 0.91 LMNA (0.60) AKR1C3AKR1C1LMNASMN1; SMN2MEN1
SCHEMBL6286906 0.91 LMNA (0.60) AKR1C3AKR1C1LMNASMN1; SMN2MEN1
SCHEMBL6285302 0.91 HTR6 (0.54) AKR1C3AKR1C1LMNASMN1; SMN2MEN1
SCHEMBL6284670 0.91 LMNA (0.51) AKR1C3AKR1C1LMNASMN1; SMN2MEN1
SCHEMBL6285310 0.91 HTR6 (0.54) AKR1C3AKR1C1LMNASMN1; SMN2MEN1
SCHEMBL6284673 0.91 LMNA (0.51) AKR1C3AKR1C1LMNASMN1; SMN2MEN1
SCHEMBL6278581 0.90 LMNA (0.50) AKR1C3AKR1C1LMNASMN1; SMN2MEN1
SCHEMBL6278533 0.90 LMNA (0.53) AKR1C3AKR1C1LMNASMN1; SMN2MEN1
SCHEMBL6278583 0.90 LMNA (0.50) AKR1C3AKR1C1LMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A AKR1C3 1869/4885AKR1C1 2552/4885LMNA 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.